Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
| 対象疾患 | Asthma |
|---|---|
| 相 | 第2相 |
| スポンサー | ARS Pharmaceuticals, Inc. |
| ステータス | 完了 |
| 参加者数 | 18 名 |
| 介入（薬剤） | ARS-1 1 mg, Albuterol MDI, ARS-1 2mg |
| 開始日 | 2022年7月28日 |
| 完了日 | 2024年2月2日 |
| 結果公開日 | 2026年7月14日 |
概要
ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
Effect of ARS-1 Versus Albuterol and Placebo
| ARS-1 1mg | 0.150 ± 0.223 FEV1 L per hour |
|---|---|
| ARS-1 2mg | 0.233 ± 0.216 FEV1 L per hour |
| Placebo | -0.002 ± 0.118 FEV1 L per hour |
| Albuterol | 0.378 ± 0.265 FEV1 L per hour |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
- Developing a Childhood Asthma Risk Passive Digital Marker — Indiana University
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With C — Chiesi Farmaceutici S.p.A.
- A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
- A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
- Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Sev — AstraZeneca